Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A paper has been published today, first authored by a member of SITU and which includes Doug Altman as a co-author where they discuss the usage of sample size and conclude that there are substantial variations in practice exist with awareness, use, and willingness to recommend methods varying substantially.

The findings support the view that sample size calculation is a more complex process than would appear to be the case from trial reports and protocols. Guidance on approaches for sample size estimation may increase both awareness and use of appropriate formal methods.

Read the article at: http://ctj.sagepub.com/content/early/2014/03/06/1740774514521907

 

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.